Themis Medicare shines on entering into a License and Supply Agreement with Novartis India

15 Apr 2013 Evaluate

Themis Medicare is currently trading at Rs. 63.90, up by 3.65 points or 6.06% from its previous closing of Rs. 60.25 on the BSE.

The scrip opened at Rs. 64.00 and has touched a high and low of Rs. 64.50 and Rs. 62.00 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 120.60 on 13-Nov-2012 and a 52 week low of Rs. 49.00 on 22-Mar-2013.

Last one week high and low of the scrip stood at Rs. 64.80 and Rs. 55.15 respectively. The current market cap of the company is Rs. 51 crore.

The promoters holding in the company stood at 69.70% while Institutions and Non-Institutions held 4.49% and 25.81% respectively. 

Themis Medicare (Themis) has entered into a License and Supply Agreement with Novartis India (Novartis) on March 26, 2013. As per agreement, Themis has agreed to manufacture and supply Diclofenac topical gel formulated using unique TPM transdermal drugs delivery system in finished dosage pharmaceutical form on certain commercial terms and conditions. Novartis has agreed to purchase the same.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×